Dimerix
Business Services · Australia · 11-50 Employees
View Company Info for Free
Overview
Headquarters
425 Smith St, Fitzroy, Victoria, 3065, A...Phone Number
+61 1300813321Website
www.dimerix.comRevenue
<$5 MillionStock Symbol
DXBIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Dimerix
Founded in 2004, based out of Australia, Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 was identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Receptor-HIT is licensed non-exclusively to Excellerate Bioscience, a UK-based pharmacological assay service provider with a worldwide reputation for excellence in the field of molecular and cellular pharmacology.Explore more
Dimerix Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dimerix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Dimerix
Check if Dimerix has recently received funding, and reach out quickly before it becomes old news!
Check out if Dimerix is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Dimerix recently announced quarterly report
Funding: Get notified immidiatlly once Dimerix has new funding data
Dimerix, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Dimerix had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Dimerix launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Dimerix
Compare insights from companies similar to Dimerix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dimerix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Dimerix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Dimerix.
Dimerix financials insights
Gather financial insights about Dimerix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Share Placement
$20M
2023
Other Financing Round
$8.7M
Dimerix Tech Stack
A closer look at the technologies used by Dimerix
Most Recent Scoops
Project
expects to achieve several milestones in Q3 and Q4 2025, including outcomes from the PFIZER opportunity, FDA feedback, a blinded interim analysis, full recruitment for the DMX-200 clinical trial, and the introduction of additional pipeline opportunities.
Product Development, Pharmaceuticals, Clinical Operations
Project
Dimerix is exploring accelerated approval pathways for DMX-200 in focal segmental glomerular sclerosis (FSGS) across multiple territories, including Europe and Japan, while continuing to collect both proteinuria and eGFR data for two years to meet global regulatory requirements.
Governmental Affairs & Regulation, Pharmaceuticals, Clinical Operations, Regulations
Project
Dimerix is participating in an FDA-led working group focused on determining appropriate endpoints for focal segmental glomerular sclerosis (FSGS) clinical trials. The group has confirmed eGFR as a validated endpoint and recognized proteinuria as a potential earlier indicator of efficacy.
Governmental Affairs & Regulation, Pharmaceuticals, Clinical Operations, Regulations
Project
Dimerix is conducting a phase three clinical study for DMX-200 (ketodrol) in focal segmental glomerular sclerosis (FSGS), a rare kidney disease with no available treatments. The drug has orphan drug designation, providing advantages such as a faster route to market, pricing incentives, and market exclusivity.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Medical Research, Pharmaceuticals, Clinical Operations
Dimerix News & Media
DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia 500,000-1 million people are estimated to be living with FSGS in the territories[1] Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481[2] million, plus royalties US$10 million (~AU$14.1 million2) upfront payment Up to US$330 million (~AU$467 million2) in potential milesBLINDED ASSESSMENT OF ACTION3 STATISTICAL ASSUMPTIONS COMPLETE
Key Highlights: An external statistical blinded review of ACTION3 data has achieved its objective by confirming that the study remains appropriately statistically powered (>90%) to demonstrate a treatment effect for the primary study endpoint of proteinuria; meaning that if DMX-200 continues to reduce proteinuria in trial patients as anticipated, then there is a >90% chance that the study will successfully show a statistically significant proteinuria treatment effect at the trial's conclusion ToDMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT
Recruitment successfully completed in Dimerix' ACTION3 Phase 3 clinical trial[1], which has recruited and dosed its target 286th adult patient The ACTION3 Phase 3 trial explores the efficacy and safety of DMX-200 in FSGS patients when dosed in combination with standard-of-care blood...Dimerix and Amicus to commercialise DMX-200 in US
Dimerix will receive an upfront payment of $30m from Amicus and up to $75m in development and regulatory milestone payments.
Read more news
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding Dimerix
Sign Up For FreeTo access detailed company insights
Founded in 2004, based out of Australia, Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets. Dimerix is currently developing its proprietary product DMX-200 for both Diabetic Kidney Disease and Focal Segmental Glomerulosclerosis (FSGS). DMX-200 wa... Read More
